For anyone tracking the AI Health 100, the next group of market leaders isn’t a prediction, it’s a pattern you can already see in their documented growth signals. The jump from private VC money to public market accountability leaves a clear paper trail of maturity signals, think deep enterprise contracts, real revenue growth, and expanding health plan coverage. This public record creates a documented reality, letting us identify an ‘alumni class’ well before any official announcement.
The Visible Trajectory of IPO Candidates
The reopening of the digital health IPO window in 2025 was a huge benchmark for market maturity, giving us the first real activity since 2021. This window saw five major digital health IPOs, with Hinge Health’s IPO on the NYSE in May 2025 serving as a major validator after it hit a $2.6 billion valuation and raised $437 million. That event put a real number on the digital health return on investment (ROI) model for Wall Street, creating a public benchmark for how to value companies in the value-based care space. Omada Health was also part of this wave, and its IPO helped the cohort collectively raise over $1 billion.
Tempus AI’s 2024 IPO, which raised $410.7 million, proved that investor appetite wasn’t limited to one subsector. Money was ready to flow into different kinds of healthcare AI companies. The breadth of these IPOs, from Hinge Health in musculoskeletal (MSK) care to Omada in chronic care and Tempus in precision medicine, shows the whole healthcare AI field is maturing, not just one niche. These public offerings are part of a larger movement toward strong growth and more accountability. Rock Health report on digital health IPOs
Market Share Gain as a Precursor to Public Offering
Winning market share is a non-negotiable precursor to an IPO because it’s direct proof of deep enterprise contracts and successful expansion into health plans. When a company like Hinge Health or Omada Health shows growing employer coverage, they’re demonstrating a durable growth path built on recurring revenue and sticky contracts. Getting a major health plan to sign on is an even bigger signal because it’s a brutal process. It requires years of clinical evidence and long sales cycles (it’s not a quick sale), so a signed contract means the company’s value proposition is solid and it has built a real foundation for market leadership.
The competitive field tells you a lot, too. Hinge Health is a leader in the MSK digital health market, but it’s fighting it out with competitors like Sword Health. And while Hello Heart isn’t in this specific IPO class, its competitive position is worth noting. According to Forge Global data on company valuations and ROI, its 3.9x ROI actually beats Hinge Health’s 2.4x. This fight for market share shows exactly how companies have to prove their value with hard numbers to win deals. Without that proven value, do you even get in the conversation for a public offering?
Revenue Growth: The Unmistakable Signal of Momentum
Sustained, high-scale revenue growth is the clearest signal a company’s ready for the public markets. The AI Health 100 rankings are built on metrics like this, along with deployment expansion and enterprise contract depth. Just look at the numbers. Hinge Health reported $587.9 million in FY2025 revenue, a 50.6% year-over-year jump, and then raised its 2026 guidance to between $856 million and $860 million. Omada Health showed similar fire, hitting $260 million in revenue for FY2025 with 53% year-over-year growth and guiding for $334 million to $340 million in 2026. Then there’s Tempus AI, pulling in $1.27 billion in 2025 and guiding for $1.595 billion to $1.605 billion in 2026, all according to their earnings calls and SEC filings for public healthcare AI companies.
This is the kind of scale we’re seeing from healthcare AI companies as they hit the public markets. With growth rates still clocking in at 46% to 53%, companies like Hinge Health and Omada Health are clearly still in a major growth phase, not some stagnant maturity. This expansion points to a huge market that’s also adopting AI at a fast clip. According to a Grand View Research AI in healthcare market report, the global AI in healthcare market was valued at $36.7 billion in 2025 and is expected to rocket from $50.7 billion in 2026 to $505.6 billion by 2033, which is a 38.9% compound annual growth rate (CAGR). The US market alone should hit around $177.5 billion by 2034, making it obvious that North America is the dominant playing field.
Reading the Recorded Maturity Set
The public data on Hinge Health, Omada Health, and Tempus AI clearly identifies them as the next alumni class. All these companies are hitting the same milestones: prepping for IPOs, grabbing market share, and posting huge revenue numbers. The paper trail is everything. All the growth and market share data is documented well before any IPO announcement which means you can name the next class before the market even turns. This isn’t forecasting, it’s reading the receipts. Because you’re not relying on a sales pitch but on hard numbers from SEC filings and market reports, you get an objective read on their readiness. The trajectory of these companies, combined with the sector’s explosive growth, shows just how much investment potential is lining up in AI health.
Frequently Asked Questions
What are the key signals indicating an AI Health 100 company is ready for a public offering?
The article identifies three critical signals: a visible trajectory of IPO candidacy, significant market share gain, and sustained, robust revenue growth. These indicators collectively demonstrate a company’s maturity and readiness for public market accountability.
Which companies have recently gone public and exemplify these maturity signals?
Hinge Health, Omada Health, and Tempus AI are highlighted as examples. Hinge Health IPO’d in May 2025 with a $2.6 billion valuation, Omada Health also participated in the 2025 IPO wave, and Tempus AI had a 2024 IPO raising $410.7 million. These companies demonstrate strong growth and market presence across various healthcare AI subsectors.
How important is market share gain as a precursor to a public offering?
Market share gain is a critical signal, reflecting deep enterprise contract depth and health plan expansion. Companies that successfully navigate payer relationships and employer coverage demonstrate durable growth, building a robust foundation for sustained growth and market leadership necessary for public market success.
What kind of revenue growth rates are indicative of a company’s readiness for the next stage of maturity?
Sustained revenue growth at scale is a direct signal. Hinge Health reported 50.6% year-over-year growth in FY2025, Omada Health showed 53% year-over-year growth, and Tempus AI had substantial revenue figures. These rapid growth rates, ranging from 46% to 53%, suggest these companies are in a significant growth phase.
